

# Marc S Sabatine

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2725829/marc-s-sabatine-publications-by-year.pdf>

**Version:** 2024-04-16

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

439  
papers

54,307  
citations

106  
h-index

229  
g-index

501  
ext. papers

67,886  
ext. citations

12.9  
avg, IF

7.42  
L-index

#	Paper	IF	Citations
439	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.. <i>Diabetes Care</i> , <b>2022</b> , 45, e27-e29	14.6	1
438	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.. <i>Clinical Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	14
437	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 104-118	7.9	0
436	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 52-64	7.9	1
435	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. <i>American Heart Journal</i> , <b>2022</b> , 243, 147-157	4.9	1
434	Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.. <i>Circulation: Cardiovascular Interventions</i> , <b>2022</b> , CIRCINTERVENTIONS121011382	6	1
433	Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 306-318	7.9	1
432	No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0266615	3.7	0
431	Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.. <i>Circulation</i> , <b>2022</b> ,	16.7	8
430	Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And Lipoprotein(a) reduction-DOSE Finding Study) Trial.. <i>American Heart Journal</i> , <b>2022</b> , 251, 61-61	4.9	1
429	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , <b>2021</b> ,	16.7	1
428	Acute Coronary Syndrome <b>2021</b> , 59-80		
427	Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. <i>Lancet, The</i> , <b>2021</b> ,	40	17
426	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2021</b> ,	18.1	3
425	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	5
424	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , <b>2021</b> , CIRCHEARTFAILURE121008837	7.6	2
423	Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. <i>JAMA Cardiology</i> , <b>2021</b> ,	16.2	7

422	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , <b>2021</b> , 44, 586-594	14.6	24
421	Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1499-1507	15.1	4
420	LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2021</b> , 41, 3005-3014	9.4	2
419	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1026-1036	12.3	16
418	Effect of dapagliflozin on anaemia in DAPA-HF. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 617-628	12.3	14
417	Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. <i>Archives of Cardiovascular Diseases</i> , <b>2021</b> , 114, 187-196	2.7	0
416	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , <b>2021</b> , 44, 1159-1167	14.6	7
415	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 601-613	12.3	14
414	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2P-TIMI 50. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e018673	6	3
413	Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017401	6	6
412	PCSK9 Inhibition-A Tale of 2 Potential Treatment Opportunities-Reply. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 481	16.2	
411	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 254-264	7.9	23
410	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , <b>2021</b> , 143, 1962-1972	16.7	13
409	Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. <i>Circulation Journal</i> , <b>2021</b> , 85, 2063-2070	2.9	1
408	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 499-507	16.2	35
407	Myocardial Infarction and Evolocumab-Reply. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1222-1223	16.2	
406	Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2822-2845	15.1	4
405	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 678-689	16.2	7

404	Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. <i>Circulation</i> , <b>2021</b> , 144, 249-251	16.7	0
403	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1298-1305	16.2	2
402	Differentiating Type 1 and Type 2 Myocardial Infarction: Unfortunately, Still More Art Than Science. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 781	16.2	2
401	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. <i>Diabetes Care</i> , <b>2021</b> , 44, 1805-1815	14.6	10
400	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 139-147	16.2	16
399	Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 675-681	5.1	3
398	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. <i>Circulation</i> , <b>2021</b> , 143, 298-309	16.7	69
397	Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 259-267	15.1	5
396	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , <b>2021</b> , 143, 470-478	16.7	13
395	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 29-38	6.7	11
394	Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2021</b> , 14, e009759	6	0
393	Recombinant human Lecithin-Cholesterol acyltransferase in patients with atherosclerosis: Phase 2a primary results and phase 2b design. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> ,	6.4	7
392	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 632-643	12.3	8
391	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. <i>Diabetologia</i> , <b>2021</b> , 64, 1226-1234	10.3	4
390	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. <i>Circulation</i> , <b>2021</b> , 143, 685-695	16.7	3
389	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , <b>2021</b> , 14, e003006	5.2	1
388	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017008	6	6
387	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1662-1672	12.3	6

386	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 801-810	16.2	4
385	Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL. <i>Circulation</i> , <b>2021</b> , 144, 1732-1734	16.7	2
384	Assessment of the Change of a Continuous Variable as a Function of its Initial Value-Reply. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1342-1343	16.2	
383	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , <b>2021</b> , 42, 3727-3738	9.5	22
382	Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020446	6	1
381	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	1
380	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 2573-2581	14.6	0
379	Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	5
378	Letter to the editor re: Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 281-282	3.8	1
377	Association of APOE genotype and lipid lowering with cognitive function in a randomized placebo-controlled trial of Evolocumab. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e047188	1.2	
376	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007879	7.6	7
375	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet, The</i> , <b>2020</b> , 396, 1637-1643	40	62
374	Association of Hospital-Level Differences in Care With Outcomes Among Patients With Acute ST-Segment Elevation Myocardial Infarction in China. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2021677	10.4	16
373	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 709-713	16.2	25
372	Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 787-793	16.2	11
371	Cognition After Lowering LDL-Cholesterol With Evolocumab. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2283-2293	15.1	28
370	Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e015331	6	16
369	Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1247-1258	12.3	19

368	The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Circulation</i> , <b>2020</b> , 142, 538-545	16.7	52
367	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1095-1106	15.1	12
366	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 1353-1368	17.4	155
365	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , <b>2020</b> , 41, 2379-2392	9.5	80
364	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. <i>Circulation</i> , <b>2020</b> , 141, 1600-1607	16.7	32
363	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 811-818	7.9	44
362	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1122-1131	6.7	13
361	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. <i>Circulation</i> , <b>2020</b> , 141, 1227-1234	16.7	97
360	Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 289-300	15.1	12
359	LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487320902750	3.9	22
358	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1357-1368	6.7	13
357	Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58. <i>Circulation</i> , <b>2020</b> , 142,	16.7	1
356	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> ,	3.9	5
355	Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. <i>Circulation</i> , <b>2020</b> , 141, 616-623	16.7	61
354	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , <b>2020</b> , 41, 1625-1632	9.5	19
353	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. <i>Circulation</i> , <b>2020</b> , 141, 100-111	16.7	68
352	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. <i>Circulation</i> , <b>2020</b> , 141, 90-99	16.7	130
351	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 468-475	14.6	33



350	Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2020</b> , 2048872619896205	4.3	1
349	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , <b>2020</b> , 142, 1040-1054	16.7	52
348	EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 932-933	18.1	
347	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 1255-1262	16.2	12
346	No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 1012-1014	5	3
345	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , <b>2020</b> , 142, 734-747	16.7	16
344	Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism". <i>Circulation</i> , <b>2020</b> , 142, e264	16.7	0
343	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , <b>2020</b> , 43, 2878-2881	14.6	8
342	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. <i>Circulation</i> , <b>2020</b> , 142, 1623-1632	16.7	20
341	Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial". <i>Circulation</i> , <b>2020</b> , 142, e129-e130	16.7	4
340	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , <b>2020</b> , 41, 3402-3418 <sup>40</sup>	9.5	236
339	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , <b>2020</b> , 41, 111-188	9.5	2236
338	Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. <i>Stroke</i> , <b>2020</b> , 51, 1546-1554	6.7	35
337	Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. <i>JAMA Cardiology</i> , <b>2020</b> ,	16.2	4
336	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 952-957	16.2	22
335	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 140, 1569-1577	16.7	57
334	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , <b>2019</b> , 290, 140-205	3.1	259
333	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1381-1391	27.4	79

332	SGLT-2 inhibitors for people with type 2 diabetes - Authors Reply. <i>Lancet, The</i> , <b>2019</b> , 394, 560-561	40	4
331	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1995-2008	59.2	2021
330	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. <i>Circulation</i> , <b>2019</b> , 140, 1308-1317	16.7	85
329	Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 364-373	27.4	263
328	Correctly understanding the diabetes data in FOURIER. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2342-2343	27.4	263
327	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2019</b> , 5, 200-206	6.4	17
326	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2019</b> , 7, 606-617	18.1	304
325	Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2961-2970	15.1	59
324	Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 613-619	16.2	41
323	Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 600-601	16.2	41
322	Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e011444	6	4
321	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 665-675	12.3	145
320	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , <b>2019</b> , 139, 2516-2527	16.7	142
319	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 139, 2528-2536	16.7	283
318	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. <i>Cell</i> , <b>2019</b> , 177, 231-242	56.2	91
317	The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1402-1411	12.3	103
316	PCSK9 inhibitors: what we know, what we should have understood, and what is to come. <i>European Heart Journal</i> , <b>2019</b> ,	9.5	2
315	Impact of ADCY9 Genotype on Response to Anacetrapib. <i>Circulation</i> , <b>2019</b> ,	16.7	19



314	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , <b>2019</b> , 12, 1521-1537	5	189
313	Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2132-2146	15.1	58
312	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 899-911	18.1	61
311	244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial. <i>Diabetes</i> , <b>2019</b> , 68, 244-OR	0.9	9
310	Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 462-470	12.3	20
309	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 139, 2022-2031	16.7	345
308	Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus". <i>Circulation</i> , <b>2019</b> , 140, e740-e741	16.7	4
307	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. <i>Circulation</i> , <b>2019</b> , 140, 2108-2118	16.7	13
306	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 3013-3022	15.1	30
305	Current Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease: The PEACE Trial. <i>Circulation</i> , <b>2019</b> , 140, 2044-2046	16.7	2
304	Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. <i>European Heart Journal</i> , <b>2019</b> , 40, 2775-2781	9.5	61
303	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 347-357	59.2	2455
302	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet</i> , <b>2019</b> , 393, 31-39	40	1300
301	PCSK9 inhibitors: clinical evidence and implementation. <i>Nature Reviews Cardiology</i> , <b>2019</b> , 16, 155-165	14.8	84
300	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , <b>2019</b> , 139, 366-375	16.7	21
299	Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 59-63	16.2	24
298	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , <b>2019</b> , 139, 1483-1492	16.7	288
297	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 473-480	16.2	21

296	Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. <i>Circulation</i> , <b>2018</b> , 138, 756-766	16.7	136
295	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 489-496	15.1	41
294	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , <b>2018</b> , 200, 83-89	4.9	89
293	Questioning the safety and benefits of evolocumab - Authors Reply. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 11-12	18.1	1
292	DECLARE-TIMI 58: Participants Baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1107-1108	11.0	1108
291	Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by Subgroups. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 108	15.1	1
290	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. <i>American Heart Journal</i> , <b>2018</b> , 202, 39-48	4.9	12
289	Inflammatory and Cholesterol Risk in the FOURIER Trial. <i>Circulation</i> , <b>2018</b> , 138, 131-140	16.7	127
288	Genomics-Guided Antithrombotic Therapy for Acute Coronary Syndromes <b>2018</b> , 147-161		
287	Clinical benefits of evolocumab appear less than hoped - Authors Reply. <i>Lancet, The</i> , <b>2018</b> , 391, 934-935	4.0	2
286	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , <b>2018</b> , 137, 684-692	16.7	10
285	Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 823-828	16.2	102
284	Coding variants in and increase risk of atrial fibrillation. <i>Communications Biology</i> , <b>2018</b> , 1, 68	6.7	21
283	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1107-1117	59.2	143
282	Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2018</b> , 11, e006084	6	4
281	Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 749-753	16.2	66
280	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). <i>Circulation</i> , <b>2018</b> , 137, 338-350	16.7	348
279	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009260	6	7

278	Response by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)". <i>Circulation</i> , <b>2018</b> , 138, 222-223	16.7	9
277	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 392, 2269-2279	4 <sup>0</sup>	46
276	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , <b>2018</b> , 39, 3810-3820	9.5	18
275	Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2018</b> , 23, 423-432	2.6	7
274	Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 317, 440	27.4	
273	Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 556-560	16.2	15
272	Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 59-65	3.3	38
271	How We Evaluate Biomarker Studies. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 524	16.2	2
270	Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 598-607	16.2	97
269	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1713-1722	59.2	27 <sup>00</sup>
268	Potent P2Y Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1549-1559	15.1	36
267	A Missense Variant in PLEC Increases Risk of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2157-2168	15.1	43
266	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1069-1078	16.2	91
265	Evolocumab in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 787-8	59.2	21
264	Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban). <i>Circulation</i> , <b>2017</b> , 136, 1895-1907	16.7	23
263	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2017</b> , 5, 941-950	18.1	33 <sup>0</sup>
262	Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1368-1375	15.1	50
261	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 527-538	15.1	17

260	Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 935-936	16.2	16
259	PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity-Reply. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1169	16.2	3
258	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 633-643	59.2	263
257	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1997	59.2	17
256	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1385-1391	16.2	62
255	Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism". <i>Circulation</i> , <b>2017</b> , 136, 120-121	16.7	
254	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 947-956	27.4	169
253	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 940-947	7	20
252	Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. <i>Lancet, The</i> , <b>2017</b> , 390, 1962-1971	40	336
251	Oral dual antiplatelet therapy: what have we learnt from recent trials?. <i>European Heart Journal</i> , <b>2016</b> , 37, 344-52	9.5	11
250	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , <b>2016</b> , 37, 390-9	9.5	232
249	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. <i>European Heart Journal</i> , <b>2016</b> , 37, 400-8	9.5	54
248	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). <i>Circulation</i> , <b>2016</b> , 134, 861-71	16.7	34
247	Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 627-8	16.2	7
246	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , <b>2016</b> , 134, 304-13	16.7	102
245	Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease. <i>Circulation</i> , <b>2016</b> , 134, 270-85	16.7	114
244	Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. <i>Postgraduate Medicine</i> , <b>2016</b> , 128 Suppl 1, 31-9	3.7	4
243	The Prospects for Cardiovascular Proteomics: A Glass Approaching Half Full. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 245-6	16.2	3

242	Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 69-77	7	14
241	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1082-1115	16.7	737
240	SAFETY OF VERY LOW LDL-C LEVELS WITH EVOLOCUMAB: AN ANALYSIS OF 5942 PATIENTS FROM PHASE 2 AND 3 AND OPEN-LABEL EXTENSION STUDIES. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1868	15.1	2
239	The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. <i>American Heart Journal</i> , <b>2016</b> , 175, 193-201.e3	4.9	67
238	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 425-32	16.2	70
237	Rationale and design of the Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. <i>American Heart Journal</i> , <b>2016</b> , 173, 94-101	4.9	124
236	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1145-1154	15.1	82
235	PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 41, 374-83	5.1	22
234	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , <b>2016</b> , 37, 1133-42	9.5	103
233	Advances in the treatment of dyslipidemia. <i>Cleveland Clinic Journal of Medicine</i> , <b>2016</b> , 83, 181-6	2.8	9
232	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 322-323	15.1	11
231	Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2144-2153	59.2	418
230	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1082-1115	15.1	856
229	Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	76
228	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2719-2728	15.1	225
227	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2732-2740	15.1	141
226	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1591-9	27.4	144
225	PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor role. <i>Journal of Lipid Research</i> , <b>2016</b> , 57, 1086-96	6.3	138



224	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2015</b> , 152, 1243-1275	1.5	198
223	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 1289-97	27.4	614
222	Sharing Data from Cardiovascular Clinical Trials--A Proposal. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 407-9	59.2	33
221	Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2015</b> , 4, 431-40	4.3	13
220	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , <b>2015</b> , 385, 2280-7	40	126
219	Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 2638-2651	15.1	123
218	Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. <i>American Heart Journal</i> , <b>2015</b> , 169, 622-630.e6 <sup>4-9</sup>	4.9	27
217	Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4,	6	35
216	On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study). <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 694-8	3	11
215	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1500-9	59.2	1081
214	Long-term use of ticagrelor in patients with prior myocardial infarction. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1791-800	59.2	1193
213	Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. <i>Lancet, The</i> , <b>2015</b> , 385, 2264-2271	40	371
212	PCSK9 inhibition in patients with hypercholesterolemia. <i>Trends in Cardiovascular Medicine</i> , <b>2015</b> , 25, 567-74	6.4	20
211	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1274-5	59.2	48
210	Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. <i>Circulation</i> , <b>2015</b> , 131, 254-62	16.7	78
209	Prognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin T. <i>Clinical Cardiology</i> , <b>2015</b> , 38, 230-5	3.3	14
208	TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, B36	15.1	7
207	Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1611-53	15.1	64



206	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>American Heart Journal</i> , <b>2014</b> , 167, 437-444.e5	4.9	74
205	Lipoprotein(a) for risk assessment in patients with established coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 520-7	15.1	119
204	Diagnostic performance of copeptin in patients with acute nontraumatic chest pain: BWH-TIMI ED chest pain study. <i>Clinical Cardiology</i> , <b>2014</b> , 37, 227-32	3.3	8
203	Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. <i>Lancet, The</i> , <b>2014</b> , 384, 599-606	4.0	139
202	2014 AHA/ACC Guideline for the Management of Patients With NonST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2645-2687	15.1	132
201	Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 361-8	15.1	59
200	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, e139-e228	15.1	1822
199	Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. <i>Clinical Chemistry</i> , <b>2014</b> , 60, 158-64	5.5	59
198	AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9	15.1	42
197	monoclonal antibody inhibition combined with statin therapy-thrombolysis in myocardial infarction 57. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 430-3 Reply: limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 943	15.1	2
196	Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. <i>Circulation</i> , <b>2014</b> , 129, 234-43	16.7	180
195	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. <i>European Heart Journal</i> , <b>2014</b> , 35, 2249-59	9.5	106
194	Pharmacogenomics of antiplatelet drugs. <i>Hematology American Society of Hematology Education Program</i> , <b>2014</b> , 2014, 343-7	3.1	2
193	Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. <i>Clinical Cardiology</i> , <b>2014</b> , 37, 160-3	3.3	3
192	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , <b>2014</b> , 130, e344-426	16.7	754
191	Population and personalized medicine in the modern era. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 1969-70	27.4	21
190	The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3, e000784	6	9
189	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , <b>2014</b> , 130, 2354-94	16.7	696

188	Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1278-1288	15.1	266
187	Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2421-8	15.1	74
186	Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism. <i>PLoS ONE</i> , <b>2014</b> , 9, e99058	3.7	6
185	Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , <b>2013</b> , 166, 1043-1049.e1	4.9	9
184	Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 1966-1976	15.1	91
183	Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 310, 1145-55	27.4	45
182	Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 1275-81	5	31
181	Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 1240-9	15.1	216
180	Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2013</b> , 18, 555-9	2.6	12
179	Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2013</b> , 2, 195-202	4.3	24
178	Ticagrelor for acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 1473-84	2.5	0
177	AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody (LAPLACE-TIMI 57) Study. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 1240-9	16.7	139
176	Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. <i>Clinical Cardiology</i> , <b>2013</b> , 36, 222-7	3.3	17
175	Myocardial infarction accelerates atherosclerosis. <i>Nature</i> , <b>2012</b> , 487, 325-9	50.4	674
174	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2P-TIMI 50 trial. <i>Lancet, The</i> , <b>2012</b> , 380, 1317-24	4 <sup>0</sup>	177
173	Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. <i>Lancet, The</i> , <b>2012</b> , 380, 2007-17	4 <sup>0</sup>	327
172	The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2012</b> , 144, 762-70	1.5	9
171	Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. <i>Chronobiology International</i> , <b>2012</b> , 29, 1390-6	3.6	12

170	Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. <i>American Heart Journal</i> , <b>2012</b> , 164, 817-24.e13	4.9	16
169	Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 891-900	15.1	50
168	An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 106-11	15.1	69
167	Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 332-8	15.1	46
166	Detection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions. <i>JACC: Cardiovascular Imaging</i> , <b>2012</b> , 5, 941-55	8.4	161
165	CYP2C19 genotype and cardiovascular events. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 307, 1482-3; author reply 1484-5	27.4	9
164	Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. <i>Clinical Cardiology</i> , <b>2012</b> , 35, 385-91	3.3	37
163	Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2012</b> , 34, 222-8	5.1	9
162	Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2012</b> , 34, 229-34	5.1	16
161	Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. <i>American Journal of Human Genetics</i> , <b>2012</b> , 90, 410-25	11	214
160	A rare complication of infective endocarditis. <i>Circulation</i> , <b>2012</b> , 125, 1316-7	16.7	2
159	Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. <i>Heart</i> , <b>2012</b> , 98, 786-91	5.1	29
158	Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. <i>Circulation</i> , <b>2012</b> , 125, 233-40	16.7	109
157	Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. <i>Clinical Chemistry</i> , <b>2012</b> , 58, 257-66	5.5	115
156	Clopidogrel Dosing Based on Genotype Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 307,	27.4	5
155	Approach to the Patient with Chest Pain <b>2012</b> , 1076-1086		6
154	Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 2398-405	15.1	107
153	Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). <i>American Heart Journal</i> , <b>2011</b> , 161, 1147-55.e1	4.9	43

152	Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. <i>American Heart Journal</i> , <b>2011</b> , 162, 518-26.e5	4.9	42
151	A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. <i>Nature Biotechnology</i> , <b>2011</b> , 29, 635-43	44.5	202
150	Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients with Stable Coronary Disease. <i>Circulation</i> , <b>2011</b> , 1	16.7	
149	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. <i>American Journal of Human Genetics</i> , <b>2011</b> , 88, 6-18	11	103
148	Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 493-500	5.1	7
147	Genetic variants in the KIF6 region and coronary event reduction from statin therapy. <i>Human Genetics</i> , <b>2011</b> , 129, 17-23	6.3	15
146	Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2011</b> , 31, 203-10	9.4	103
145	Cardiology patient page. Randomized, controlled trials. <i>Circulation</i> , <b>2011</b> , 124, e832-4	16.7	1
144	Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 2556-64	27.4	944
143	Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 2221-8	27.4	268
142	Carriage of Reduced-Function CYP2C19 Allele Among Patients Treated With Clopidogrel Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 467	27.4	3
141	Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 1311-7	5.5	8
140	Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. <i>European Heart Journal</i> , <b>2011</b> , 32, 697-705	9.5	64
139	Clopidogrel and Salicylates <b>2011</b> , 139-153		
138	Risk Stratification in Unstable Angina and NonST-Segment Elevation Myocardial Infarction <b>2011</b> , 181-193		
137	Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2010</b> , 30, 2372-84	9.4	20
136	Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. <i>Critical Pathways in Cardiology</i> , <b>2010</b> , 9, 14-8	1.3	5
135	Metabolic signatures of exercise in human plasma. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 33ra37	17.5	276

134	Integration of proteomic-based tools for improved biomarkers of myocardial injury. <i>Clinical Chemistry</i> , <b>2010</b> , 56, 194-201	5.5	38
133	Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 1821-30	27.4	778
132	B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 1189-1196	15.1	61
131	Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2118-24	15.1	105
130	Case records of the Massachusetts General Hospital. Case 28-2010. A 32-year-old woman, 3 weeks post partum, with substernal chest pain. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1164-73	59.2	19
129	Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , <b>2010</b> , 159, 55-62	4.9	6
128	Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLOpidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. <i>American Heart Journal</i> , <b>2010</b> , 159, 964-971.e1	4.9	11
127	Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. <i>Lancet, The</i> , <b>2010</b> , 376, 1312-9	40	473
126	Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. <i>American Journal of Cardiology</i> , <b>2010</b> , 105, 1300-5	3	28
125	Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction <b>2010</b> , 219-233		
124	A sensitive cardiac troponin T assay in stable coronary artery disease. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2538-47	59.2	651
123	New antibody assays for cardiovascular disease: future tools for the clinical chemist?. <i>Clinical Chemistry</i> , <b>2009</b> , 55, 404-6	5.5	2
122	Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. <i>Circulation</i> , <b>2009</b> , 119, 2553-60	16.7	510
121	Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 2903-17	0.7	30
120	Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. <i>Clinical Chemistry</i> , <b>2009</b> , 55, 265-73	5.5	45
119	Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. <i>Clinical Chemistry</i> , <b>2009</b> , 55, 1108-17	5.5	219
118	Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. <i>Circulation</i> , <b>2009</b> , 119, 1195-202	16.7	28
117	Identification of genetic variants associated with response to statin therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 1310-5	9.4	67



116	Validation of an automated safety surveillance system with prospective, randomized trial data. <i>Medical Decision Making</i> , <b>2009</b> , 29, 247-56	2.5	18
115	Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. <i>Molecular and Cellular Proteomics</i> , <b>2009</b> , 8, 2339-49	7.6	250
114	Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 475-9	3	17
113	Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction. <i>American Heart Journal</i> , <b>2009</b> , 157, 517-24	4.9	16
112	Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. <i>American Heart Journal</i> , <b>2009</b> , 158, 386-91	4.9	71
111	Interaction between cigarette smoking and clinical benefit of clopidogrel. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 1273-8	15.1	98
110	The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 2290-5	15.1	94
109	The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 1935-45	15.1	103
108	Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 2290-5	15.1	82
107	Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 2261-76	15.1	33
106	Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. <i>Lancet, The</i> , <b>2009</b> , 374, 787-95	40	102
105	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. <i>Lancet, The</i> , <b>2009</b> , 374, 989-997	40	531
104	Cytochrome p-450 polymorphisms and response to clopidogrel. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 354-62	59.2	1874
103	Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. <i>European Heart Journal</i> , <b>2009</b> , 30, 162-9	9.5	187
102	Novel antiplatelet strategies in acute coronary syndromes. <i>Cleveland Clinic Journal of Medicine</i> , <b>2009</b> , 76 Suppl 1, S8-15	2.8	14
101	Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 303-7	3	55
100	Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 457-61	3	18
99	Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 1232-8	3	6



98	Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 552-8	3	36
97	Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 435-43	15.1	150
96	Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 546-51	15.1	25
95	Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 449-55	15.1	136
94	Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 2422-9	15.1	16
93	Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. <i>American Heart Journal</i> , <b>2008</b> , 155, 49-55	4.9	135
92	Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. <i>American Heart Journal</i> , <b>2008</b> , 155, 133-9	4.9	10
91	Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. <i>American Heart Journal</i> , <b>2008</b> , 155, 910-7	4.9	35
90	Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 300, 71-80	27.4	314
89	Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. <i>European Heart Journal</i> , <b>2008</b> , 29, 1096-102	9.5	138
88	Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. <i>European Heart Journal</i> , <b>2008</b> , 29, 984-91	9.5	40
87	Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 562-7	9.4	36
86	Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2008</b> , 295, L16-22	5.8	65
85	Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. <i>Circulation</i> , <b>2008</b> , 117, 1936-44	16.7	238
84	Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 3503-12	15.9	214
83	Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2008</b> , 26, 106-12	5.1	2
82	Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 2256-63	15.1	27
81	Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 205-14	15.1	177

80	Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 2117-24	15.1	122
79	Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 344-8	3	8
78	Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2007</b> , 23, 173-9	5.1	24
77	Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2007</b> , 24, 85-91	5.1	35
76	Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. <i>Circulation</i> , <b>2007</b> , 115, 3071-8	16.7	111
75	A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. <i>European Heart Journal</i> , <b>2007</b> , 28, 2070-6	9.5	7
74	Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. <i>Clinical Chemistry</i> , <b>2007</b> , 53, 1800-7	5.5	63
73	Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 2167-78	59.2	39
72	Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. <i>Circulation</i> , <b>2007</b> , 115, 1528-36	16.7	262
71	Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. <i>Chest</i> , <b>2007</b> , 131, 964-71	5.3	107
70	Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, 2463-9	9.4	96
69	Appropriate invasive and conservative treatment approaches for patients with ST-elevation MI. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2006</b> , 8, 3-11	2.1	1
68	Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 761-3	3	17
67	Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. <i>European Heart Journal</i> , <b>2006</b> , 27, 2040-5	9.5	14
66	Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. <i>Circulation</i> , <b>2006</b> , 113, e72-5	16.7	83
65	Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. <i>Circulation</i> , <b>2006</b> , 114, 550-7	16.7	148
64	Inflammatory biomarkers in acute coronary syndromes: part IV: matrix metalloproteinases and biomarkers of platelet activation. <i>Circulation</i> , <b>2006</b> , 113, e382-5	16.7	32
63	Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. <i>Circulation</i> , <b>2006</b> , 114, 281-8	16.7	239

62	Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2006</b> , 26, 2763-8	9.4	27
61	Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation. <i>Circulation</i> , <b>2006</b> , 113, e152-5	16.7	61
60	Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. <i>Circulation</i> , <b>2006</b> , 113, 1745-52	16.7	192
59	Cardiovascular genomics. <i>Circulation</i> , <b>2006</b> , 113, e450-5	16.7	11
58	Prevalence and determinants of troponin T elevation in the general population. <i>Circulation</i> , <b>2006</b> , 113, 1958-65	16.7	320
57	Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. <i>Circulation</i> , <b>2006</b> , 114, 26-31	16.7	131
56	Inflammatory biomarkers in acute coronary syndromes: part III: biomarkers of oxidative stress and angiogenic growth factors. <i>Circulation</i> , <b>2006</b> , 113, e289-92	16.7	31
55	Clopidogrel use in coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , <b>2006</b> , 4, 7-15	2.5	4
54	The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 37-42	15.1	53
53	Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 2326-31	15.1	128
52	Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. <i>American Heart Journal</i> , <b>2006</b> , 151, 25-31	4.9	16
51	Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. <i>American Heart Journal</i> , <b>2006</b> , 151, 360-6	4.9	12
50	Clopidogrel in ST-elevation myocardial infarction. <i>Country Review Ukraine</i> , <b>2006</b> , 8, G31-G34		3
49	Something old, something new: beta blockers and clopidogrel in acute myocardial infarction. <i>Lancet, The</i> , <b>2005</b> , 366, 1587-9	4.0	11
48	Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2005</b> , 5, 751-61	2.2	3
47	Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. <i>American Heart Journal</i> , <b>2005</b> , 149, 846-50	4.9	43
46	Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. <i>American Heart Journal</i> , <b>2005</b> , 149, 227-33	4.9	43
45	Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 1179-89	59.2	1508

44	Metabolomic identification of novel biomarkers of myocardial ischemia. <i>Circulation</i> , <b>2005</b> , 112, 3868-75	16.7	385
43	Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 294, 2866-71	27.4	156
42	Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 228-33	3	3
41	Platelets and atherothrombosis: An essential role for inflammation in vascular disease [A review]. <i>International Journal of Angiology</i> , <b>2005</b> , 14, 211-217	1.1	2
40	Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. <i>Circulation</i> , <b>2005</b> , 112, 3846-54	16.7	55
39	When prognosis precedes diagnosis: putting the cart before the horse. <i>Cmaj</i> , <b>2005</b> , 172, 1697-8	3.5	4
38	Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. <i>Circulation</i> , <b>2005</b> , 111, 2042-9	16.7	487
37	Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. <i>Circulation</i> , <b>2005</b> , 111, 1217-24	16.7	47
36	Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. <i>Stroke</i> , <b>2005</b> , 36, 2346-50	6.7	68
35	Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 294, 1224-32	27.4	521
34	Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. <i>Circulation</i> , <b>2004</b> , 109, 2186-90	16.7	322
33	Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction) trial. <i>Circulation</i> , <b>2004</b> , 109, 874-80	16.7	144
32	Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. <i>Circulation</i> , <b>2004</b> , 109, 874-80	16.7	53
31	Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 1362-7, A5-6	3	36
30	Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). <i>American Journal of Cardiology</i> , <b>2004</b> , 94, 774-6	3	20
29	B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 335-9	15.1	171
28	Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 1988-95	15.1	270
27	The search for a biomarker of cardiac ischemia. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 537-9	5.5	67

26	Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. <i>Circulation</i> , <b>2003</b> , 107, 690-5	16.7	368
25	Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy. <i>American Journal of Cardiology</i> , <b>2003</b> , 91, 457-61	3	24
24	Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2003</b> , 91, 1163-7	3	8
23	The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 89S-95S	15.1	53
22	Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 1264-72	15.1	338
21	Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 1396-8	5.5	47
20	Iatrogenic aortic dissection. <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 623-6	3	147
19	Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. <i>American Journal of Cardiology</i> , <b>2002</b> , 90, 303-5	3	63
18	Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. <i>Circulation</i> , <b>2002</b> , 105, 1760-3	16.7	562
17	Images in cardiovascular medicine. Fibrillary/immunotactoid glomerulopathy with cardiac involvement. <i>Circulation</i> , <b>2002</b> , 105, e120-1	16.7	9
16	The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 238-44	15.1	44
15	Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18) substudy. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 1741-9	15.1	204
14	Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. <i>American Heart Journal</i> , <b>2002</b> , 143, 966-70	4.9	25
13	Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration. <i>American Heart Journal</i> , <b>2002</b> , 144, 790-5	4.9	15
12	Elevation in serum troponin I predicts the benefit of tirofiban. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2001</b> , 11, 211-5	5.1	19
11	A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris. <i>American Journal of Cardiology</i> , <b>2001</b> , 88, 488-92	3	24
10	Refractory systemic hypertension following type B aortic dissection. <i>American Journal of Cardiology</i> , <b>2001</b> , 88, 686-8	3	24
9	The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1014-21	59.2	1046

8	Will Diabetes Save the Platelet Blockers?. <i>Circulation</i> , <b>2001</b> , 104, 2759-2761	16.7	10
7	Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2000</b> , 10, 189-96	5.1	9
6	The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. <i>American Journal of Medicine</i> , <b>2000</b> , 109, 224-37	2.4	43
5	Pulmonary cholesterol crystal embolization. <i>Chest</i> , <b>1997</b> , 112, 1687-92	5.3	26
4	Moving toward Personalized Medicine 205-227		
3	Antiplatelet Therapy in ST-Elevation Myocardial Infarction 164-177		
2	Mutations in RPL3L and MYZAP increase risk of atrial fibrillation		1
1	Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants		5